Oxford based predictive genetics company GENinCode Plc (AIM: GENI) revealed on Wednesday that it has entered into a commercial distribution agreement with Sohin Genetics to market CARDIO inCode-Score in Mexico, extending access to its polygenic risk score test for the genetic prediction and prevention of coronary heart disease.

This agreement follows a recent collaboration between GENinCode and the Mexican Association for the Prevention of Atherosclerosis, supporting education and prevention initiatives in a market of more than 130 million people where coronary heart disease is the leading cause of death. Sohin Genetics will promote CARDIO inCode-Score across its network of hospitals and clinics, providing training, sample handling and test ordering through GENinCode's SITAB international reporting system.

CARDIO inCode-Score is a clinically validated, commercially available test based on DNA from saliva or blood samples, enabling identification of inherited genetic risk of heart disease and supporting early prevention through lifestyle changes and targeted therapies. The test is designed for population-based risk prediction and primary prevention, with pricing positioned for international healthcare systems.

Integration of CARDIO inCode-Score into clinical pathways enables healthcare providers to identify individuals at elevated lifetime risk of heart disease, personalise prevention strategies and reduce the incidence and cost of severe cardiovascular events. Cardiovascular disease represents an estimated USD4.3bn market in Mexico, underlining the commercial and public health significance of the agreement.